Determination of a vancomycin nephrotoxicity threshold and assessment of target attainment in hematology patients
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.1231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Sherilyn Wong und 2 weiteren Autor:innen. Beteiligte Einrichtung: UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Vancomycin, Acute Kidney Injury, Anti-Bacterial Agents, Area Under Curve. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SA Health, The Hospital Research Foundation, University of South Australia, Allied Health Research Collaboration grant.
Abstract (Originalsprache)
An area‐under‐the‐curve (AUC 24 )‐based approach is recommended to guide vancomycin therapeutic drug monitoring (TDM), yet trough concentrations are still commonly used despite associated risks. A definitive toxicity target is lacking, which is important for hematology patients who have a higher risk of nephrotoxicity. The aims were to (1) assess the impact of trough‐based TDM on acute kidney injury (AKI) incidence, (2) establish a vancomycin nephrotoxicity threshold, and (3) evaluate the proportion of hematology patients achieving vancomycin therapeutic targets. Retrospective data was collected from 100 adult patients with a hematological malignancy or aplastic anemia who received vancomycin between April 2020 and January 2021. AKI occurrence was determined based on serum creatinine concentrations, and individual pharmacokinetic parameters were estimated using a Bayesian approach. Receiver operating characteristic (ROC) curve analysis was performed to assess the ability of pharmacokinetic indices to predict AKI occurrence. The proportion of patients who achieved target vancomycin exposure was evaluated based on an AUC 24 /MIC ≥400 and the determined toxicity threshold. The incidence of AKI was 37%. ROC curve analysis indicated a maximum AUC 24 of 644 mg.h/L over the treatment period was an important predictor of AKI. By Day 4 of treatment, 29% of treatment courses had supratherapeutic vancomycin exposure, with only 62% of courses achieving AUC 24 targets. The identified toxicity threshold supports an AUC 24 target range of 400–650 mg.h/L, assuming an MIC of 1 mg/L, to optimize vancomycin efficacy and minimize toxicity. This study highlights high rates of AKI in this population and emphasizes the importance of transitioning from trough‐based TDM to an AUC‐based approach to improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
- School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
- SA Pharmacy, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
ORCID-Profile: Sherilyn Wong, Philip R Selby, Stephanie E Reuter
Förderung
- SA Health, The Hospital Research Foundation, University of South Australia
- Allied Health Research Collaboration grant
Zitieren
APA
Wong, S., Selby, P. R., & Reuter, S. E. (2024). Determination of a vancomycin nephrotoxicity threshold and assessment of target attainment in hematology patients. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1231
Vancouver
Wong S, Selby PR, Reuter SE. Determination of a vancomycin nephrotoxicity threshold and assessment of target attainment in hematology patients. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1231
BibTeX
@article{Wong2024,
author = {Wong, Sherilyn and Selby, Philip R and Reuter, Stephanie E},
title = {Determination of a vancomycin nephrotoxicity threshold and assessment of target attainment in hematology patients},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.1231}
}
EUVIMED